What is new in treatment research for myelodysplastic syndrome?

Published on

Progress in the understanding of the biology of myelodysplastic syndrome (MDS) is driving the development of many new potential therapies. At the 20th Congress of the European Hematology Association (EHA), Dr Valeria Santini, Associate Professor of Hematology at the University of Florence, Florence, Italy, tells us about clinical studies that are looking at targeting specific pathways in this heterogeneous disease.

View more programs featuring

Page last updated on January 26, 2016